Introduction
Lung cancers are one of the most common causes of death related to cancer (approximately 18%) and approximately 3,000,000 people get cancer every year (1) . Non-small cell lung cancers (NSCLCs) constitute 75%-80% of all lung cancers (2) . The high recurrence rate (greater than 20%) after curative resection is probably due to undetermined occult-small metastatic lesions that are present at the first diagnosis (3) .
Treatment is determined predominantly by the stage of NSCLC at initial diagnosis. The accuracy of the diagnostic workup is crucial for adequate therapeutic planning. Patients with limited disease (stages I, II, and IIIA) are candidates for curative surgery. In contrast, patients with advanced disease (stages IIIB or IV) are considered to be incurable (4) . In the latter group, unnecessary surgical procedures performed with a curative intent can be avoided by accurate staging, and palliative treatment options should be considered for these patients. Patients considered for surgery undergo imaging tests such as radioisotope bone scan, computed tomography (CT) of the chest and abdomen, and CT or magnetic resonance imaging (MRI) of the brain to detect metastases in order to avoid unnecessary surgery. Recently, numerous studies have indicated that the addition of positron emission tomography (PET) or PET/CT using the glucose analog 18F-fludeoxyglucose (FDG) exhibits higher diagnostic accuracy than CT alone and is also cost-effective when implemented into the staging of NSCLC (5) (6) (7) (8) (9) .
Because PET or PET/CT is a whole-body imaging modality, it is also an efficient imaging method for assessment of thoracic and extrathoracic metastases of NSCLCs in a single session. For the patients with NSCLC, the determination rate of unknown metastases via FDG-PET or PET/CT has been found as 6%-20% (7, (10) (11) (12) . High sensitivity of the PET/CT in showing unexpected distant metastases may reduce unnecessary noncurative surgical procedures for NSCLC. Our purpose in this retrospective study is to determine the ratio of unexpected (within the coverage area of thorax CT) and unknown (outside of the coverage area of thorax CT) metastases by PET/CT in patients with newly diagnosed NSCLC who had no defined metastatic lesion in conventional thorax CT and thus to investigate the contribution of FDG-PET/ CT in metastasis staging.
FDG-PET is also a highly sensitive method for assessing solitary pulmonary nodules. In a metaanalysis (n = 1474) performed by Gould et al. it was found that, in solitary lung lesions of greater than 1 cm, the sensitivity of FDG-PET was extremely high (96.8%) and the specificity was relatively low (77.8%) (13) . Our other purpose in this study is to investigate the ratio of the unknown or unexpected metastases in patients with solitary pulmonary lesions (nodule or mass) who underwent PET/CT for metabolic characterization.
Materials and methods

PET/CT imaging and assessment protocol
PET/CT studies were performed by using a 6-slice multidetector CT integrated high-resolution PET scanner (Siemens Biograph LSO HI-REZ PET/CT, USA) on patients with a minimum 4-h fasting blood glucose level of ≤150 mg/dL and 1-1.5 h after an intravenous FDG injection.. First a topogram and then a low-dose nonenhanced CT of the region consisting of the vertexproximal femur were taken, and finally PET images of the same region were taken. In the assessment of PET/CT imaging attenuation-corrected PET images were analyzed as a standard. Nonattenuation-corrected images were also analyzed when needed. A higher FDG uptake than physiological background activity was accepted as PET positivity. Maximum standard uptake value (SUVmax) was calculated from the most active region among the PET-positive lesions.
Patient group
A total of 567 patients (489 males and 78 females, mean age 60.9 ± 10.7 years) were enrolled in this retrospective study. Among the 567 patients, a total of 156 patients who underwent FDG-PET/CT for metabolic characterization (group 1) and had solitary pulmonary nodules (spn, group 1a, n = 39) or solitary pulmonary masses (spm, group 1b, n = 117) on thorax CT and the remaining 411 patients (group 2) with a diagnosis of NSCLC who underwent FDG-PET/CT for staging formed the basis of this study.
Group 1: Metabolic characterization group
The patients with a solitary lesion of ≥1 cm in the lung parenchyma, as determined by thorax CT, were evaluated by FDG-PET/CT for metabolic characterization. A total of 156 patients (35 females, 121 males, mean age 62.6 ± 10.8) who had increased FDG uptake in the lung lesion (SUVmax of ≥2.5) were included in this group. Of the 156 patients, 39 had a solitary pulmonary nodule with increased FDG accumulation (spn, group 1a, dimensions of <3 cm) and 117 patients had a solitary pulmonary mass with increased FDG uptake (spm, group 1b, dimensions of ≥3 cm) on FDG-PET/CT.
In this patient group, verification of both the FDGpositive solitary pulmonary lesion and the lesion showing increased FDG uptake suggestive of distant metastasis was performed according to the histopathological examination or clinical-radiological follow-up results. We investigated how many of these patients had histopathologically proven intrathoracic (unexpected) or extrathoracic (unknown) metastases shown by FDG-PET/CT. Since we did not aim to investigate the role of FDG-PET/CT in the characterization of solitary pulmonary lesions, verifications of PET-negative pulmonary lesions were not done.
Group 2: Staging group
A total of 411 patients (43 females, 368 males, mean age 60.2 ± 10.6) with histopathologically proven NSCLC who underwent FDG-PET/CT for initial staging were enrolled in this group. The patients with advanced-stage disease who had known extrapulmonary lesions suggestive of distant metastases by the time of PET scan imaging were not included in the study. Similarly, the patients with defined lesions suggesting metastasis in the contralateral lung parenchyma by thorax CT examination were also excluded from the study. In this group the patients underwent FDG-PET/CT for initial staging; the distribution of the lesions with increased FDG uptake that suggested distant metastases as shown by FDG-PET/CT was recorded as intrathoracic (unexpected) or extrathoracic (unknown) metastases. Final diagnoses of lesions with increased FDG accumulation that suggested metastases on PET/ CT were made by histopathologic examination or clinicalradiological follow-up. Because the purpose of the study was not to investigate the role of PET/CT in N staging of the lung cancers, N1, N2, and N3 situations were not examined.
Statistical analysis
In the metabolic characterization groups (group 1a and group 1b), the SUVmax values and the dimensions of solitary lung lesions were compared with determination of metastasis by using the t-test. In the staging group (group 2), SUVmax values of the primary lesion and the determination of metastasis were compared by using the t-test. In the staging group, the incidence of metastasis according to the T stage of primary lesion was also compared by applying the chi-square test.
Results
No increased FDG uptake focus suggesting distant metastasis was observed in 32 of 39 patients with a solitary pulmonary nodule (group 1a) who were examined with FDG-PET/CT. However, true positive distant metastases were determined in 5 (12.8%) of these patients. Two of them had brain metastasis (outside of the thorax CT coverage area), 1 had metastatic lesions in ribs of the left hemithorax and metastatic lymphadenopathies (LAPs) in the left axilla (within the thorax CT coverage area), 1 patient had metastatic multiple lesions in the skeletal system and a metastatic lesion in the liver (within and outside of the thorax CT coverage area, Figure 1 ), and 1 patient had metastatic lesions in both adrenals and the peritoneum and metastatic multiple lesions in the skeletal system (within and outside of the thorax CT coverage area) ( Table 1) . On the other hand, there was a false-positive focus with increased FDG uptake suggesting distant metastasis in 2 patients (1 of them had slightly increased FDG uptake focus in the left adrenal and the other had slightly increased FDG accumulation in the left femoral neck and right scapula).
In group 1a, SUVmax value and lesion size of solitary pulmonary nodules were compared with the presence of metastases in the 32 patients who had no increased FDG uptake suggestive of distant metastases and in the 5 patients with true positive distant metastases on FDG-PET/CT by using the t-test ( Table 2 ). The mean SUVmax of the solitary pulmonary nodules was 11.87 ± 6.65 in the 32 cases with no FDG uptake suggestive of distant metastases and 12.00 ± 2.39 in the 5 cases with true positive metastases, which was not statistically significantly different (P = 0.937). Mean lesion size was 18.25 ± 4.36 mm in cases with no FDG uptake suggestive of distant metastases and 21.80 ± 5.36 mm in cases with true positive metastases, which was not statistically significantly different (P = 0.219).
Among the 117 patients who had solitary pulmonary mass of ≥3 cm on thorax CT and who demonstrated Figure 1 . PET/CT images of a 59-year-old female patient with solitary pulmonary nodule in the upper lobe of the left lung determined by thorax CT. There was a hypermetabolic nodular lesion in the left upper lobe, which was compatible with primary tumor (first row). There were also metastatic hypermetabolic LAPs in the bilateral mediastinal lymphatic stations (second row). Apart from those, a hypermetabolic lesion compatible with the unknown metastasis was observed in the inferior section of the right liver lobe (third row), and unexpected and unknown metastatic lesions were determined in the skeletal system (last row).
increased tracer accumulation at the pulmonary lesion on FDG-PET/CT, which was performed for metabolic characterization (group 1b), 85 had no increased FDG accumulation suggestive of distant metastasis. On the other hand, distant metastasis (true positive increased FDG uptake focus) was detected in 29 patients (24.8%) (Figure 2) . Of the 29 patients with true positive distant metastasis, 8 had intrathoracic, 5 had extrathoracic, and 16 had both intra-and extrathoracic distant metastases (Table 1) . However, false positive increased FDG uptakes were observed in 3 patients (slightly increased FDG uptake at the 3rd rib in 1 patient, at the corpus of the 12th dorsal vertebrae in 1 patient, and at the transverse process of the 6th cervical vertebrae in 1 patient).
The detection of metastasis was compared with the SUVmax value and size of solitary pulmonary mass by using a t-test in the 85 patients who had no metastatic finding on FDG-PET/CT and in the 29 patients with true Of the 411 patients with histopathologically proven NSCLC who underwent FDG-PET/CT for initial staging (group 2) and had no findings of metastasis on previously performed thorax CT, 43 had T -I, 169 had T -II, 177 had T -III, and 22 had T -IV stage tumors. In 265 of 411 patients, there was no increased FDG uptake to suggest distant metastasis. On the other hand, 17 patients had false positive increased FDG uptake suggesting distant metastasis (solitary skeletal uptake system in 5 patients, multiple skeletal uptake in 1, solitary adrenal uptake in 3, skeletal and adrenal uptake in 1, multiple skeletal and solitary other foci in 2, solitary liver uptake in 1, and uptake at the other structures in 4 patients). On the other hand, distant metastasis (true positive increased FDG uptake) was observed in 129 of the 411 patients in this group (31.4%) (Figures 3 and 4) . Among these patients with distant metastasis, 42 had metastasis within the thorax area, 29 had metastasis outside the thorax area, and 58 had metastasis in both areas. The distribution of the metastatic lesions according to the T stage of the primary tumor is given in Table 4 . When the frequency of metastasis was compared with the T stage of primary lung tumor using the chi-square test, we found that the frequency of metastasis increased as the T stage increase (P = 0.086) ( Table 5 ).
The SUVmax value of the primary lung lesion and determination of metastasis was compared by applying the t-test in the 265 patients with no increased FDG uptake Figure 2 . A 58-year-old male patient with left upper lung lobe mass who was imaged by PET/CT for metabolic characterization. In the left upper lobe, a mass with malignant hypermetabolism, indicating a primary tumor, was seen (first row). Hypermetabolic LAPs consistent with metastases were seen at the left lower paratracheal and left hilar areas in the mediastinum (second row). PET/CT images also determined unexpected metastatic hypermetabolic lesions in the left lobe of the liver and in the right adrenal (third row). Additionally, there were unexpected metastatic lesions and unknown metastatic lesions in the skeletal system (last row).
to suggest distant metastasis and in the 129 patients with true positive metastasis (Table 6 ). Mean SUVmax of the primary tumor in the 265 cases with no metastasis was 16.86 ± 6.39, while it was 15.96 ± 7.11 in the 129 cases with metastasis, which did not demonstrate any statistically significant difference (P = 0.225). PET/CT images of a 62-year-old male patient with NSCLC located in the right lower lung lobe. Intense FDG uptake (right bottom corner, maximum intensity projection image) was observed in the known primary lung tumor. While there was no pathologic uptake in the N2-N3 mediastinal lymphatic stations and in the adrenals, a subcentimetric focus with slightly increased FDG uptake was determined on the right side of the L3 vertebrae corpus, suggesting metastasis. This lesion was histopathologically confirmed as metastasis.
Discussion
The accurate demonstration of metastasis in NSCLC is essentially important for the selection of the best possible treatment modality and prognosis assessment. The presence of distant metastasis (M1) takes the patient to stage IV, where palliation is indicated instead of curative treatments. Approximately 20% of patients who undergo treatment for localized disease will develop metastases later because of unknown-undetected metastases that were actually present during the initial staging (3). In other words, the 5-year survival rate of less than 60% after curative surgical interventions was mostly due to undetermined distant metastasis in the initial period. Distant organ metastasis was found in 40% of the patients at initial diagnosis. The most common extrathoracic metastatic regions were the brain (43%), adrenals (40%), liver (40%), bone (33%), kidneys (23%), and abdominal lymph nodes (30%) (14, 15) . Generally contrast-enhanced thorax CT is used for the staging of lung cancers (16, 17) . However, the sensitivity, specificity, and accuracy of this method are limited. Because FDG-PET can image the whole body in a single session it is an efficient method for finding unexpected metastases of lung cancers (18) . It has been reported that FDG-PET has higher sensitivity, specificity, and accuracy when compared to contrastenhanced CT in NSCLC staging (19) (20) (21) (22) (23) .
In the studies in which the efficiency of FDG-PET/ CT in determination of distant metastases in NSCLC was assessed, it was found that the best noninvasive method was FDG-PET/CT (11, (24) (25) (26) (27) . Unknown metastases were determined by FDG-PET/CT in 10%-20% of cases with NSCLC (7, 11, 12) . In our study, PET/CT detected unexpected-unknown distant metastases in 163 of 567 patients (28.8%). A 63-year-old male patient with diagnosis of NSCLC who underwent PET/CT for staging. Thorax CT showed a mass lesion at the superior segment of the right lower lobe and N2 mediastinal lymph nodes. PET/CT images demonstrated hypermetabolic lesion at the known tumoral lesion (first row). There were also metastatic LAPs with intense hypermetabolism at the right hilar and subcarinal region in the mediastinum (second row). Additionally, bilateral metastatic lesions in the adrenals (third row) and multiple metastatic lesions in the skeletal system (last row) were noted. In the determination of distant metastasis in nonsmall cell lung cancers it was reported that the sensitivity of FDG-PET/CT was 90%-100% and its specificity was 79.2%-96.4% (28) (29) (30) (31) . In a metaanalysis that investigated the role of FDG-PET in detection of distant metastasis, the sensitivity, specificity, and accuracy values were found to be 94%, 97%, and 96%, respectively (10) . The accuracy of detecting distant metastases by FDG-PET and FDG-PET/ CT, except in the brain, was found to be higher than that of other imaging modalities (32) . Because intense FDG uptake is normally seen in the brain cortex, the efficiency of FDG-PET is low in the detection of brain metastases. FDG-PET can detect unexpected brain metastasis in only 0.4%-1.5% of cases (33, 34) . However, current PET/ CT systems are expected to have higher detection rates because of their higher resolution limit. In our study, PET/ CT detected brain metastasis in 5 of the group 1 patients (3 of whom had isolated brain metastasis) and 12 of the group 2 patients (6 of whom had isolated brain metastasis).
FDG-PET has superior sensitivity and specificity than CT in the detection of liver, bone, and extrathoracic lymph node metastasis as well as secondary malignity (25, 35) . The sensitivity, specificity, and false negativity of FDG-PET/CT in detecting adrenal metastasis were 98%, 92%, and 3.8%, respectively (36) (37) (38) . We demonstrated unknown adrenal metastasis in 9 [isolated adrenal metastasis in 3 patients (2 unilateral, 1 bilateral)] patients in group 1 and 38 [12 patients with isolated adrenal metastasis (10 unilateral, 2 bilateral)] patients in group 2 by PET/CT.
In a study with a limited number of patients, the sensitivity and specificity of PET in the determination of liver metastases in NSCLC was reported as 100% (39) . In our study, 6 of the group 1 patients (isolated liver metastasis in 1 patient) and 22 of the group 2 patients (isolated brain metastasis in 2 patients) had liver metastasis.
FDG-PET/CT was also found to be a beneficial method in the determination of bone metastases and its efficiency in the determination of sternum and vertebra metastases was higher than that with CT (40) . Bone scintigraphy has high sensitivity and low specificity in determining metastases, but it is limited to the skeletal system. The sensitivity of bone scintigraphy in osteolytic metastases is also low. When compared to a bone scan, FDG-PET was reported to have higher specificity and comparable sensitivity in the determination of bone metastases (41) . In our study, 18 of the group 1 patients (2 of them within the coverage area of thorax CT, 2 outside of the coverage area, and 14 within and outside of the coverage area) and 83 of the group 2 patients (18 of them within the coverage area of thorax CT, 15 outside of the coverage area, and 50 within and outside of the coverage area) had bone metastases. In a study comparing bone scintigraphy and FDG-PET in the detection of bone metastasis in newly diagnosed lung cancers, the sensitivity, specificity, and accuracy of FDG-PET were found to be superior to bone scintigraphy (42) . In another study, it was shown that FDG-PET/CT has higher sensitivity, specificity, and positive/negative predictive values in the determination of bone metastases than bone scintigraphy (43) . In light of such data, it can be predicted that FDG-PET/CT may replace bone scintigraphy in the determination of bone metastases of lung cancers. Unexpected distant metastasis were found in 8% of stage I tumor, 18% of stage II tumor, and 24% of stage III tumor patients in a series with various disease stages by using PET (39, 44, 45) . In our study, metastases were determined in 7 of 43 (16.3%) cases with T -I stage, 51 of 169 (30.2%) cases with T -II stage, 62 of 177 (35.0%) cases with T -III stage, and 9 of 22 (40.9%) cases with T -IV stage by FDG-PET/CT performed for initial staging. It is remarkable that the incidence of metastasis increases as the T stage increases. However, this was not found to be statistically significant, probably because of the unequal distribution of the patient numbers in each stage.
It was reported that using FDG-PET in the staging of potentially operable non-small cell lung cancers prevented unnecessary thoracotomies in 20% of cases (46) . FDG-PET/CT was superior to conventional methods in determining unknown metastasis in lung cancers and upstages the disease in 25%-40% of cases (5, 47) .
Additionally, increased FDG uptake in PET or PET/ CT images is not specific to metastasis. It is known that FDG can accumulate in various inflammatory processes, as well. In our study, false positive increased FDG uptake was seen in 5 (3.2%) of 156 patients in the metabolic characterization group. On the other hand, in the staging group, false positive increased FDG uptake was observed in 17 (4.1%) of 411 patients. Therefore, it is required to be more careful in assessing especially solitary lesions, cases with low SUVmax values (low FDG accumulation), and cases in which corresponding CT images are incompatible and upstage the disease by PET/CT. Histopathological verification should be made in order to avoid false positive results.
There were 2 limitations to our study. The first limitation is that histopathological confirmation of FDG positives for all lesions was not available. Most of the cases were verified by clinical or radiological methods. The second limitation is that the rate of false negative PET/CT was not examined because the PET/CT study was not compared with any other imaging modality such as whole-body bone scan, CT, MRI, or sodium fluoride-PET.
In conclusion, being a whole-body imaging modality, PET/CT is an effective imaging method in the assessment of both thoracic and extrathoracic lesions in only one session. Demonstration of distant metastases in NSCLCs is crucial to determine treatment modality and prognosis, and it generally leads to nonsurgical and palliative therapies instead of curative treatments. Determining unexpected metastatic lesions with FDG-PET/CT imaging performed for benign/malignant differential diagnosis of solitary lung lesions, and detecting unexpected-unknown metastatic lesions in patients with a diagnosis of NSCLC who underwent FDG-PET/CT for staging, proves that FDG-PET/CT is an extremely useful imaging method in assessing lung lesions and planning the treatment for lung cancers. Thus, FDG-PET/CT imaging should be performed in the evaluation of all pulmonary lesions with suspicion of malignancy and in the initial staging of all patients with a diagnosis of NSCLC.
